This approval was based on the outcome of the CheckMate-037 trial, which revealed improved objective response rates to nivolumab versus investigator’s choice chemotherapy in patients with unresectable or metastatic melanoma whose cancers had progressed following treatment with ipilimumab ± a BRAF inhibitor [20]. This evidence concerns the gene BRAF and metastatic melanoma.